If you felt whiplash reading recent headlines about estrogen and perimenopause—you’re not alone.

At the 2025 Menopause Society Annual Meeting, a research poster analyzing data from more than 120 million women unexpectedly ignited a media firestorm. News outlets quickly framed the findings as proof that starting estrogen in perimenopause prevents breast cancer, heart attacks, and stroke—sparking viral conversations that went far beyond what the data can actually support.

In this episode of Sky Women’s Health, Dr. Carolyn Moyers is joined by Dr. Rachel Pope, MD, gynecologist, menopause specialist, and mentor on the research team behind the poster, to slow the conversation down and bring clarity back to the science.

Together, we unpack what the study really showed, what was lost in translation, and how women should interpret this information when making decisions about hormone therapy.

Why This Study Caught Fire

* The study used a massive electronic health record database of over 120 million patient records

* It compared women who started estrogen:

* during perimenopause

* after menopause

* or never used estrogen

* It examined rates of breast cancer, heart attack, and stroke

* Media headlines quickly implied causation—despite this being a retrospective, observational study

What the Data Actually Showed

* Women who used estrogen during perimenopause (within 10 years before menopause) did not have higher rates of breast cancer, heart attack, or stroke compared with the other groups

* These findings support the idea that earlier initiation may be safe and potentially beneficial—but do not prove protection or prevention

* The results align with the broader timing hypothesis of hormone therapy, but do not settle the debate

Critical Limitations That Didn’t Make the Headlines

* This study relied on diagnosis codes, not individual chart review

* It did not analyze:

* type of estrogen

* dose or route

* type of progestin

* There was no breakdown by race, ethnicity, or other demographic factors

* Because perimenopausal women are younger, some conditions (like breast cancer or cardiovascular disease) may simply not have occurred yet during the study’s timeframe

* Like all retrospective studies, it cannot determine cause and effect

Why This Still Matters for Women

* Many women experience significant symptoms during perimenopause, often years before their final period

* Hormone therapy can be life-changing for symptoms and quality of life

* This study helps normalize thoughtful, earlier conversations—but it does not replace individualized medical decision-making

* Observational data like this helps generate hypotheses and funding for future prospective trials, which we still urgently need

The Real Takeaway

This study doesn’t mean everyone should start estrogen in perimenopause—and it doesn’t mean estrogen prevents disease. What it does mean is that earlier use appears reassuringly safe in this dataset, and that women deserve nuanced, evidence-based counseling rather than fear-driven or headline-driven decisions.

If you’re navigating perimenopause, the most important factors remain:

* your symptoms

* your health history

* your goals

* your personal risk profile

* shared decision-making with a menopause-informed clinician

Resources Mentioned

* The Menopause Society provider directory at Menopause.org for finding evidence-based menopause care

🔗 Connect with Dr. Carolyn Moyers

📸 Instagram: @drcarolynmoyers

🎥 YouTube: @drcarolynmoyers

🌐 Website: www.skywomenshealth.com